PA 1050040

Drug Profile

PA 1050040

Alternative Names: PA-040; PA-1050040

Latest Information Update: 03 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panacos Pharmaceuticals Inc
  • Class Antivirals
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 25 Jul 2007 Data presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS-2007) added to the Viral Infections antimicrobial activity and pharmacokinetics sections
  • 28 Feb 2007 Phase-I clinical trials in HIV infections treatment in USA (PO)
  • 28 Dec 2006 Preclinical trials in HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top